Find your next M&A target
Target Asia + Worldwide M&A projects with our guidance on matching, planning, due diligence & implementation.
Israeli Bladder Cancer Treatment Company Seeks to Sell 100% Equity
|Total value of the target||N/A|
|Expected target net rate of return after deducting all taxes and fees||N/A|
|Validity period of pending order||365|
Senior Associate, International Business Advisory
|Project highlights||USD 1M sales – 20 years track record – new to China & USA|
The Israeli company has developed and commercialized a device for the treatment of Non-muscle Invasive Bladder Cancer (NMIBC). The company’s device has a CE mark and is currently considered by the European Association of Urology (EAU) and the National Institute for Health and Care Excellence (NICE) as one of only few reliable and effective treatments for NMIBC. The company has performed 40,000 treatments in the past 20 years in Europe (incl. UK), Turkey and Israel. The founder and inventor seek to sell the company to concentrate on R&D.
Enquire for more information about our services, and how we can help solve challenges for your organizationContact Us